GLP-1 RAs reached 8.73% of prescriptions in September 2026. Explore the latest trends in tirzepatide, semaglutide, orforglipron, and first-time prescribing.
Need help?
Contact usGLP-1 RAs reached 8.73% of prescriptions in September 2026. Explore the latest trends in tirzepatide, semaglutide, orforglipron, and first-time prescribing.